$8.34
0.020.24%
Last update: Nov 6, 4:00 PM
Atrium Therapeutics Inc (RNA) Stock Price, Quote, News & History
RNANASDAQ
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.
You can purchase shares of Atrium Therapeutics (NASDAQ:RNA) through any online brokerage.
Other companies in Atrium Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Atrium Therapeutics has a consensus price target of $57.62.
The stock price for Atrium Therapeutics (NASDAQ: RNA) is $8.34 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Atrium Therapeutics.
Atrium Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Atrium Therapeutics.
Atrium Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue...
